MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 9.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,830 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Celldex Therapeutics worth $1,080,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in CLDX. Vanguard Group Inc. lifted its stake in shares of Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock worth $98,098,000 after purchasing an additional 12,213 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after buying an additional 676,771 shares during the last quarter. Deep Track Capital LP bought a new stake in shares of Celldex Therapeutics in the 4th quarter valued at about $38,919,000. Rock Springs Capital Management LP grew its position in shares of Celldex Therapeutics by 10.7% in the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company’s stock worth $30,885,000 after buying an additional 118,404 shares during the last quarter. Finally, Novo Holdings A S raised its stake in shares of Celldex Therapeutics by 3.8% during the 4th quarter. Novo Holdings A S now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $25,270,000 after acquiring an additional 36,337 shares in the last quarter.

Analyst Upgrades and Downgrades

CLDX has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Morgan Stanley decreased their price target on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Finally, Canaccord Genuity Group began coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a “buy” rating and a $64.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.90.

Celldex Therapeutics Stock Down 0.1%

Shares of NASDAQ CLDX opened at $20.35 on Monday. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The business’s 50 day moving average price is $18.91 and its 200 day moving average price is $22.35. The firm has a market cap of $1.35 billion, a P/E ratio of -7.92 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.